1. (1) As required or authorized by Sections 26B-1-202, 26B-7-202, and 26B-7-207, each entity shall report to the department every event of:

   1. (a) acute flaccid myelitis;
   2. (b) adverse event resulting from smallpox vaccination (vaccinia virus, orthopox virus);
   3. (c) anaplasmosis (Anaplasma phagocytophilum);
   4. (d) anthrax (Bacillus anthracis) or anthrax-like illness caused by any Bacillus cereus strain that expresses any anthrax toxin gene;

   5. (e) an antibiotic-resistant organism, from any specimen, that:

      1. (i) is resistant to vancomycin in Staphylococcus aureus (VRSA); or

      2. (ii) is resistant to a carbapenem in:

         1. (A) Acinetobacter species;
         2. (B) any Enterobacterales organism, including:
         3. (I) Enterobacter species;
         4. (II) Escherichia coli; or
         5. (III) Klebsiella species; or
         6. (C) Pseudomonas aeruginosa that is also not susceptible to;
         7. (I) ceftolozane/tazobactam; or
         8. (II) cefepime or ceftazidime when ceftolozane/tazobactam resistance is unknown; or

      3. (iii) demonstrates carbapenemase production in:

         1. (A) Acinetobacter species;
         2. (B) any Enterobacterales organism, including:
         3. (I) Enterobacter species;
         4. (II) Escherichia coli; or
         5. (III) Klebsiella species; or
         6. (C) Pseudomonas aeruginosa;

   6. (f) arbovirus disease, including:

      1. (i) chikungunya virus disease;
      2. (ii) Oropouche virus disease, congenital and non-congenital;
      3. (iii) St. Louis encephalitis virus disease;
      4. (iv) West Nile virus disease; and
      5. (v) Zika disease including congenital;
   7. (g) babesiosis (Babesia spp.);

   8. (h) botulism (Clostridium botulinum);

      1. (i) brucellosis (Brucella spp.);
   9. (j) campylobacteriosis (Campylobacter spp.);

   10. (k) Candida auris or Candida haemulonii from any body site;

       1. (l) Chagas disease (Trypanosoma cruzi);
   11. (m) chancroid (Haemophilus ducreyi);
   12. (n) chickenpox (varicella zoster virus or VZV, human herpesvirus 3 or HHV-3);
   13. (o) chlamydia (Chlamydia trachomatis);
   14. (p) coccidioidomycosis (Coccidioides spp.), also known as valley fever;
   15. (q) Colorado tick fever (Colorado tick fever virus, Coltivirus spp.), also known as American mountain tick fever;
   16. (r) novel coronavirus disease including Middle East respiratory syndrome (MERS-CoV), and severe acute respiratory syndrome (SARS-CoV);
   17. (s) COVID-19 (SARS-CoV-2);
   18. (t) Cronobacter sakazakii, from a normally sterile site, in a person less than 12 months old;

   19. (u) cryptosporidiosis (Cryptosporidium spp.);

       1. (v) cyclosporiasis (Cyclospora spp.);

   20. (w) dengue fever (dengue virus);

       1. (x) diphtheria (Corynebacterium diphtheriae);
   21. (y) ehrlichiosis (Ehrlichia spp.);
   22. (z) Shiga toxin-producing Escherichia coli (STEC) infection;

   23. (aa) Free-living amebae, from any human source;

       1. (i) acanthamoeba spp.;
       2. (ii) Balamuthia mandrillaris (B. mandrillaris);
       3. (iii) Naegleria fowleri (N. fowleri);
   24. (bb) giardiasis (Giardia spp.);
   25. (cc) gonorrhea (Neisseria gonorrhoeae), including sexually transmitted and ophthalmia neonatorum;
   26. (dd) Haemophilus influenzae, invasive;
   27. (ee) hantavirus infection (Sin Nombre virus);
   28. (ff) hemolytic uremic syndrome, postdiarrheal;

   29. (gg) hepatitis, viral, including:

       1. (i) hepatitis A;
       2. (ii) hepatitis B (acute, chronic, and perinatal);
       3. (iii) hepatitis C (acute, chronic, and perinatal);
       4. (iv) hepatitis D; and
       5. (v) hepatitis E;

   30. (hh) human immunodeficiency virus (HIV) infection, including acquired immune deficiency syndrome (AIDS);

       1. (ii) influenza virus infection:
       2. (i) associated with a hospitalization;
       3. (ii) associated with a death in a person under 18 years of age; or
       4. (iii) suspected or confirmed to be caused by a non-seasonal influenza strain;
   31. (jj) Legionellosis (Legionella spp.), also known as Legionnaires' disease;

   32. (kk) leptospirosis (Leptospira spp.);

       1. (ll) listeriosis (Listeria spp., including Listeria monocytogenes);
   33. (mm) Lyme disease (Borrelia burgdorferi, Borrelia mayonii);
   34. (nn) malaria (Plasmodium spp.);
   35. (oo) measles (rubeola);
   36. (pp) melioidosis (Burkholderia pseudomallei);
   37. (qq) meningococcal disease (Neisseria meningitidis), invasive;
   38. (rr) mpox;
   39. (ss) mumps (mumps virus);

   40. (tt) mycobacterial infections, including:

       1. (i) tuberculosis (Mycobacterium tuberculosis complex);
       2. (ii) leprosy (Mycobacterium leprae), also known as Hansen's disease; or
       3. (iii) any other mycobacterial infections (Mycobacterium spp.);

   41. (uu) pertussis (Bordetella pertussis);

       1. (vv) plague (Yersinia pestis);

   42. (ww) poliomyelitis (poliovirus), paralytic and nonparalytic;

       1. (xx) psittacosis (Chlamydophila psittaci), also known as ornithosis;
   43. (yy) Q fever (Coxiella burnetii);
   44. (zz) rabies (rabies virus), human and animal;
   45. (aaa) relapsing fever (Borrelia spp.), tick-borne;
   46. (bbb) rubella (rubella virus), including congenital syndrome;
   47. (ccc) salmonellosis (Salmonella spp.);
   48. (ddd) shigellosis (Shigella spp.);
   49. (eee) smallpox (Variola major and Variola minor);
   50. (fff) spotted fever rickettsioses (Rickettsia spp.), including Rocky Mountain spotted fever (Rickettsia rickettsii);

   51. (ggg) streptococcal disease, invasive, due to:

       1. (i) Streptococcus pneumoniae;
       2. (ii) group A streptococcus (Streptococcus pyogenes); or
       3. (iii) group B streptococcus (Streptococcus agalactiae);

   52. (hhh) Syphilis (Treponema pallidum), including:

       1. (i) any stage;
       2. (ii) congenital; and
       3. (iii) syphilitic stillbirths;
       4. (iii) tetanus (Clostridium tetani);
   53. (jjj) toxic shock syndrome, staphylococcal (Staphylococcus aureus) or streptococcal (Streptococcus pyogenes);

   54. (kkk) transmissible spongiform encephalopathies (prion diseases), including Creutzfeldt-Jakob disease;

       1. (lll) trichinellosis (Trichinella spp.);
   55. (mmm) tularemia (Francisella tularensis);
   56. (nnn) typhoid (Salmonella typhi), cases and carriers;
   57. (ooo) vibriosis (Vibrio spp.), including cholera (Vibrio cholerae);

   58. (ppp) viral hemorrhagic fevers including:

       1. (i) Ebola virus disease (Ebolavirus spp.);
       2. (ii) Lassa fever (Lassa virus); and
       3. (iii) Marburg fever (Marburg virus); or
   59. (qqq) yellow fever (yellow fever virus).

2. (2) Pregnancy is a reportable event for a subset of communicable diseases, and reporting is required even if the communicable disease was reported to the department before the pregnancy. Perinatally transmissible conditions reportable by an entity are any:

   1. (a) hepatitis B infection;
   2. (b) hepatitis C infection;
   3. (c) HIV infection;
   4. (d) listeriosis;
   5. (e) Oropouche virus disease;
   6. (f) rubella;
   7. (g) syphilis infection; or
   8. (h) Zika virus disease.

3. (3) Antimicrobial susceptibility tests reportable by an entity are as follows:

   1. (a) full panel antimicrobial susceptibility test results, including minimum inhibitory concentration and results suppressed to the ordering clinician, are reportable when performed on the following organisms:

      1. (i) Candida auris or Candida haemulonii from any body site;
      2. (ii) Mycobacterium tuberculosis;
      3. (iii) Neisseria gonorrhoeae;
      4. (iv) Salmonella species;
      5. (v) Shigella species;
      6. (vi) Streptococcus pneumoniae;
      7. (vii) Staphylococcus aureus from any specimen that is resistant to vancomycin (VRSA); or

      8. (viii) organisms resistant to a carbapenem in:

         1. (A) Acinetobacter species;
         2. (B) any Enterobacterales organism, including:
         3. (I) Enterobacter species;
         4. (II) Escherichia coli; or
         5. (III) Klebsiella species; or
         6. (C) Pseudomonas aeruginosa that is also not susceptible to;
         7. (I) ceftolozane/tazobactam; or
         8. (II) cefepime or ceftazidime when ceftolozane/tazobactam resistance is unknown;

   2. (b) individual carbapenemase test results including positive, negative, equivocal, indeterminate and the method used, are reportable when performed on an organism resistant to a carbapenem, or with demonstrated carbapenemase, in:

      1. (i) Acinetobacter species;

      2. (ii) any Enterobacterales organism, including:

         1. (A) Enterobacter species;
         2. (B) Escherichia coli; or
         3. (C) Klebsiella species; or
      3. (iii) Pseudomonas aeruginosa; or
   3. (c) antiviral susceptibility test results, including nucleotide sequencing, genotyping, or phenotypic analysis, are reportable when performed on HIV.

4. (4) Unusual events reportable by each entity include at least one case or suspect case of a communicable disease, condition, or syndrome considered:

   1. (a) rare, unusual, or new to Utah;
   2. (b) previously controlled or eradicated;
   3. (c) caused by an unidentified or newly identified organism;
   4. (d) due to exposure or infection from a bioterrorism event with transmission to the public; or
   5. (e) any other infection not explicitly identified in Subsection (1) that the department considers a public health hazard.

5. (5) Outbreaks, epidemics, or unusual occurrences of events reportable by an entity are as follows:

   1. (a) the entity shall report two or more cases or suspect cases, with or without an identified organism, including:

      1. (i) gastrointestinal illnesses;
      2. (ii) respiratory illnesses;
      3. (iii) meningitis or encephalitis;
      4. (iv) infections caused by antimicrobial resistant organisms;
      5. (v) illnesses with suspected foodborne or waterborne transmission;
      6. (vi) illnesses with suspected ongoing transmission in any facility;
      7. (vii) infections that may indicate a bioterrorism event; or
      8. (viii) any other infections not explicitly identified in Subsection (1) that the department considers a public health hazard;
   2. (b) the entity shall report any increase or shift in pharmaceutical sales that may indicate a change in disease trends.

6. (6)(a) In addition to laboratory results set forth in Subsections (1) through (5), each category one laboratory or category two laboratory shall include laboratory results for, or laboratory results that provide presumptive evidence of, the following communicable diseases:

   1. (i) influenza virus;

      1. (ii) norovirus infection;
      2. (iii) respiratory syncytial virus (RSV);
      3. (iv) Streptococcal disease, invasive due to any species; or
      4. (v) toxoplasmosis.

   2. (b) Each category one laboratory or category two laboratory shall include any laboratory results, including positive, negative, equivocal, or indeterminate, associated with the following tests or conditions:

      1. (i) CD4+ T-Lymphocyte tests, regardless of known HIV status;
      2. (ii) chlamydia;
      3. (iii) Clostridioides difficile;
      4. (iv) cytomegalovirus (CMV), congenital for a person up to 12 months old;
      5. (v) gonorrhea;
      6. (vi) hepatitis A;
      7. (vii) hepatitis B, including viral loads;
      8. (viii) hepatitis C, including viral loads;
      9. (ix) HIV, including viral loads and confirmatory tests;
      10. (x) liver function tests, including ALT, AST, and bilirubin associated with a viral hepatitis case;
      11. (xi) measles (rubeola);
      12. (xiii) syphilis; or
      13. (xiv) tuberculosis.
   3. (c) The department may identify additional reporting criteria when necessary for the management of an outbreak or identification of an exposure, in accordance with Title 26B, Chapter 7, Part 2, Detection and Management of Chronic and Communicable Diseases and Public Health Emergencies.

   4. (d) Non-positive laboratory results reported for any event identified in Subsection (6)(b) will be used to:

      1. (i) determine when a previously reported case becomes non-infectious;
      2. (ii) identify any newly acquired infection through identification of a seroconversion window; or
      3. (iii) provide information critical for assignment of a case status.

   5. (e) The department keeps information associated with a non-positive laboratory result for 18 months.

      1. (i) At the end of the 18-month period, if the result has not been appended to an existing case, any personal identifier is deleted from the result.
      2. (ii) The de-identified result is added to a de-identified, aggregate data set.

      3. (iii) The data set is kept for use by the department to:

         1. (A) analyze trends associated with testing patterns and case distribution; and
         2. (B) identify and establish prevention and intervention efforts for at-risk populations.

7. (7)(a) A university or hospital that conducts research studies exempt from reporting AIDS and HIV infection under Section 26B-7-203 must seek written approval of reporting exemption from the department institutional review board before the study commencement.

   1. (b) The university or hospital shall submit the following to the department within 30 days of department institutional review board approval:

      1. (i) a summary of the research protocol, including funding sources and justification for requiring anonymity; and
      2. (ii) written approval from the department institutional review board.
   2. (c) The university or hospital shall submit a report that includes each of the indicators specified in Subsection 26B-7-203(4)(a) to the department annually during an ongoing research study.
   3. (d) The university or hospital shall submit a final report that includes each of the indicators specified in Subsection 26B-7-203(4)(a) to the department within 30 days of the conclusion of the research study.
   4. (e) Any document pertaining to a reporting exemption in Subsection (7) may be submitted to the department by email to dhhs_irb@utah.gov or by mail to 288 N. 1460 West, Salt Lake City, Utah 84116.

KEY: communicable diseases, quarantines, rabies, rules and procedures

Date of Last Change: June 1, 2026

Notice of Continuation: March 2, 2026

Authorizing, and Implemented or Interpreted Law: 26B-1-202; 26B-7-202; 26B-7-207; 26B-7-303 through 26B-7-315; 26B-7-316 through 26B-7-324